Kennedy’s New Peptide Policy: What It Means for Patients

This article is for general education. It is not medical advice. Talk with a licensed clinician before starting any peptide.

The short version: On October 28, 2026, Health Secretary Robert F. Kennedy Jr. announced that the federal government will not take enforcement action against licensed pharmacies and physicians that compound six popular peptides: BPC-157, TB-500, MOTS-c, epitalon, KPV and semax. None of them is FDA-approved. The move gives patients a legal, prescription-based route to these products for the first time in years, but it does not mean the government has found them safe or effective.

What changed

In 2023 the FDA moved several of these peptides onto a list of substances that compounding pharmacies should not use, citing safety concerns. The new HHS policy sets that aside for these six peptides under specific conditions. HHS says it will not act against state-licensed pharmacies, federal facilities or licensed physicians that compound them, as long as they follow the rules below.

Kennedy described the policy as giving patients “a more controlled alternative.” An HHS spokesperson was equally clear about the limits: the policy “does not grant FDA approval or establish clinical safety and effectiveness.”

The six peptides and how they may be given

• BPC-157 — injection, oral or topical
• TB-500 — injection only
• MOTS-c — injection only
• Epitalon — injection only
• KPV — topical or oral only
• Semax — nasal spray only

Most people who use these peptides want help with healing: injuries, tendons, ligaments and joints, muscle recovery, gut problems, skin and inflammation. BPC-157 and TB-500 are the best-known recovery peptides. KPV is used mainly for inflammation in the gut and skin, and semax is promoted for focus and brain health. Those claims rest mostly on animal and lab studies, not on solid human trials. Our peptide therapy guide walks through what has actually been studied.

The rules pharmacies and doctors must follow

• A prescription for a specific patient is required. No prescription, no legal product.
• The raw ingredient must come from an FDA-registered manufacturer that follows good manufacturing practices.
• Each batch needs a certificate of analysis showing identity, purity, strength and testing for contaminants such as endotoxins and heavy metals.
• One active ingredient per product — no peptide “stacks” in a single vial.
• Serious side effects and quality problems must be reported to the FDA’s MedWatch system and state regulators.
• Products must be labeled as compounded and not for resale.

Why FDA scientists objected

The decision followed a July 2026 meeting of the FDA’s Pharmacy Compounding Advisory Committee. FDA staff opposed adding every one of these peptides. Their concerns included thin clinical data, inconsistent quality from batch to batch, and the risk of harmful immune reactions. FDA reviewers reported finding only a handful of small studies on BPC-157 and no human safety studies for KPV, TB-500, MOTS-c or epitalon. When the FDA restricted these substances in 2023, it pointed to reports of allergic reactions, kidney problems and tumor growth.

The committee’s votes were narrow. A compounding industry group reported that BPC-157, KPV and TB-500 each passed 8–6. One other candidate, emideltide, was rejected.

What it means if you are considering peptides

• Go through a licensed clinician. The legal route now runs through a doctor’s prescription and a licensed compounding pharmacy.
• Avoid “research use only” products. Peptides sold online as research chemicals are not covered by this policy. There is no doctor involved and no guarantee of what is in the vial. One lab test of a store-bought peptide product found no peptide in it at all.
• Ask to see the certificate of analysis. A reputable provider and pharmacy should be able to show it.
• Expect to pay cash. Compounded peptides are unlikely to be covered by insurance.
• Ask hard questions. What is the evidence for my condition? What side effects have you seen? How will we know if it is working, and when do we stop?

What happens next

This is an interim policy. It stays in place until the FDA writes a final rule, and the FDA has not yet proposed one. The policy was scheduled for publication in the Federal Register on October 30, 2026, with public comments accepted through November 13, 2026 (docket HHS-OASH-2026-0496). The advisory committee is expected to review another group of peptides by the end of February 2027.

Find a peptide therapy provider

Browse peptide therapy providers in our directory, read our peptide therapy guide, or use our tips on how to find a regenerative medicine provider. Listings on Regen Provider Guide are not endorsements; always confirm credentials and ask about pricing and evidence before you commit.

Sources

• CBS News: RFK Jr. to ease access to unapproved peptides, draft policy states (Oct. 28, 2026)
• Medical Daily: HHS lets pharmacies compound BPC-157 and five other unapproved peptides (Oct. 29, 2026)
• ABC News: FDA advisers narrowly vote to add 6 peptides to a drug compounding list (July 2026)
• CNN: RFK Jr. acts to ease access to unproven peptides despite opposition from FDA scientists (Oct. 28, 2026)

Photo: U.S. Department of Health and Human Services official portrait of Secretary Robert F. Kennedy Jr.